The "mosaic" embryo: misconceptions and misinterpretations in preimplantation genetic testing for aneuploidy

Fertil Steril. 2021 Nov;116(5):1205-1211. doi: 10.1016/j.fertnstert.2021.06.027. Epub 2021 Jul 23.

Abstract

Preimplantation genetic testing for aneuploidy (PGT-A) remains one of the most controversial topics in reproductive medicine. With more than 40% of in vitro fertilization cycles in the United States reportedly involving PGT, both those in favor of and those opposed to PGT-A have significant interest in the efficacy of PGT-A. Ongoing issues include what patient population, if any, benefits from PGT-A, the true frequency of chromosomal mosaicism, whether embryonic aneuploidies self-correct, and how practitioners manage embryos designated as "mosaic." This review addresses several misconceptions and misinterpretations of data surrounding the genetic analysis and prediction of mosaicism in the preimplantation embryo.

Keywords: Blastocyst; mosaicism; preimplantation genetic testing.

Publication types

  • Review

MeSH terms

  • Aneuploidy
  • Blastocyst / pathology*
  • Embryo Transfer
  • Female
  • Genetic Counseling
  • Genetic Testing*
  • Humans
  • Infertility / diagnosis
  • Infertility / physiopathology
  • Infertility / therapy*
  • Male
  • Mosaicism*
  • Predictive Value of Tests
  • Pregnancy
  • Prenatal Diagnosis*
  • Reproducibility of Results
  • Reproductive Techniques, Assisted / adverse effects*
  • Risk Assessment
  • Risk Factors
  • Treatment Outcome